{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T09:34:09Z","timestamp":1793352849849,"version":"4.5.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002973","name":"Daiichi Sankyo Co., Ltd.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gastric Cancer"],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>\nThe Cancer-VTE Registry was a large-scale, multicenter, prospective registry designed to investigate real-world data on venous thromboembolism (VTE) incidence and risk factors in adult Japanese patients with solid tumors. This pre-specified subgroup analysis aimed to estimate the incidence of VTE, including VTE types other than symptomatic VTE, and identify risk factors of VTE in stomach cancer from the Cancer-VTE Registry.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>\nStage II\u2013IV stomach cancer patients who planned to initiate cancer therapy and underwent VTE screening within 2\u00a0months before registration were enrolled.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of 1,896 patients enrolled, 131 (6.9%) had VTE at baseline, but 96.2% were asymptomatic. Female sex, age\u2009\u2265\u200965\u00a0years, VTE history, and D-dimer\u2009&gt;\u20091.2\u00a0\u03bcg\/mL were independent risk factors of VTE at baseline. Notably, patients with D-dimer\u2009&gt;\u20091.2\u00a0\u00b5g\/mL at the time of cancer diagnosis had an approximately 20-fold risk of VTE. During follow-up, event incidences were symptomatic VTE, 0.3%; incidental VTE requiring treatment, 1.1%; composite VTE, 1.4%; bleeding, 1.6%; cerebral infarction\/transient ischemic attack\/systemic embolic events, 0.7%; and all-cause death, 15.0%. The incidence of all-cause death was higher in patients with VTE vs without VTE at baseline (adjusted hazard ratio 1.67; 95% confidence interval 1.21\u20132.32; p\u2009=\u20090.002).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>VTE prevalence at the time of cancer diagnosis was not negligible and was extremely high when the patients had high D-dimer. VTE screening by D-dimer before starting cancer treatment is advisable, even for asymptomatic patients, regardless of whether the patient is undergoing surgery or chemotherapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>UMIN000024942.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10120-023-01378-1","type":"journal-article","created":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T05:45:46Z","timestamp":1680500746000},"page":"493-503","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Incidence and risk factors for venous thromboembolism in the Cancer-VTE Registry stomach cancer subcohort"],"prefix":"10.1007","volume":"26","clinical-trial-number":[{"clinical-trial-number":"umin000024942","registry":"10.18810\/umin-japan"}],"author":[{"given":"Takaki","family":"Yoshikawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Sano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Terashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensei","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etsuro","family":"Bando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryohei","family":"Kawabata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Yabusaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisashi","family":"Shinohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari S.","family":"Oba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Takita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuru","family":"Sasako","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,1]]},"reference":[{"key":"1378_CR1","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1001\/archinte.160.6.809","volume":"160","author":"JA Heit","year":"2000","unstructured":"Heit JA, Silverstein MD, Mohr DN, Petterson TM, O\u2019Fallon WM, Melton LJ 3rd. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med. 2000;160:809\u201315.","journal-title":"Arch Intern Med"},{"key":"1378_CR2","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1016\/j.ejca.2012.10.021","volume":"49","author":"AJ Walker","year":"2013","unstructured":"Walker AJ, Card TR, West J, Crooks C, Grainge MJ. Incidence of venous thromboembolism in patients with cancer - a cohort study using linked United Kingdom databases. Eur J Cancer. 2013;49:1404\u201313.","journal-title":"Eur J Cancer"},{"key":"1378_CR3","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1001\/jama.293.6.715","volume":"293","author":"JW Blom","year":"2005","unstructured":"Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005;293:715\u201322.","journal-title":"JAMA"},{"key":"1378_CR4","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jaccao.2021.03.001","volume":"3","author":"L Gervaso","year":"2021","unstructured":"Gervaso L, Dave H, Khorana AA. Venous and arterial thromboembolism in patients with cancer: JACC: CardioOncology state-of-the-art review. JACC CardioOncol. 2021;3:173\u201390.","journal-title":"JACC CardioOncol"},{"key":"1378_CR5","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1001\/archinte.166.4.458","volume":"166","author":"HK Chew","year":"2006","unstructured":"Chew HK, Wun T, Harvey D, Zhou H, White RH. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med. 2006;166:458\u201364.","journal-title":"Arch Intern Med"},{"key":"1378_CR6","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1007\/s00268-014-2763-0","volume":"39","author":"DX Yeo","year":"2015","unstructured":"Yeo DX, Junnarkar S, Balasubramaniam S, Tan YP, Low JK, Woon W, et al. Incidence of venous thromboembolism and its pharmacological prophylaxis in Asian general surgery patients: a systematic review. World J Surg. 2015;39:150\u20137.","journal-title":"World J Surg"},{"key":"1378_CR7","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1111\/jth.12611","volume":"12","author":"HY Yhim","year":"2014","unstructured":"Yhim HY, Jang MJ, Bang SM, Kim KH, Kim YK, Nam SH, et al. Incidence of venous thromboembolism following major surgery in Korea: from the health insurance review and assessment service database. J Thromb Haemost. 2014;12:1035\u201343.","journal-title":"J Thromb Haemost"},{"key":"1378_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-028563","volume":"9","author":"AO Aonuma","year":"2019","unstructured":"Aonuma AO, Nakamura M, Sakamaki K, Murai T, Matsuda C, Itaya K, et al. Incidence of cancer-associated thromboembolism in Japanese gastric and colorectal cancer patients receiving chemotherapy: a single-institutional retrospective cohort analysis (Sapporo CAT study). BMJ Open. 2019;9: e028563.","journal-title":"BMJ Open"},{"key":"1378_CR9","unstructured":"International Agency for Research on Cancer, World Health Organization. Global Cancer Observatory. https:\/\/gco.iarc.fr\/. Accessed 22 Aug 2022."},{"key":"1378_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-018910","volume":"8","author":"Y Ohashi","year":"2018","unstructured":"Ohashi Y, Ikeda M, Kunitoh H, Sasako M, Okusaka T, Mukai H, et al. Venous thromboembolism in patients with cancer: design and rationale of a multicentre, prospective registry (Cancer-VTE Registry). BMJ Open. 2018;8: e018910.","journal-title":"BMJ Open"},{"key":"1378_CR11","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1093\/jjco\/hyaa112","volume":"50","author":"Y Ohashi","year":"2020","unstructured":"Ohashi Y, Ikeda M, Kunitoh H, Sasako M, Okusaka T, Mukai H, et al. Venous thromboembolism in cancer patients: report of baseline data from the multicentre, prospective cancer-VTE Registry [published correction appears in\u00a0Jpn J Clin Oncol. 17 2020;50:1346] Jpn J Clin Oncol. 2020;50:1246\u201353.","journal-title":"Jpn J Clin Oncol"},{"key":"1378_CR12","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.thromres.2021.09.012","volume":"213","author":"Y Ohashi","year":"2022","unstructured":"Ohashi Y, Ikeda M, Kunitoh H, Sasako M, Okusaka T, Mukai H, et al. One-year incidence of venous thromboembolism, bleeding, and death in patients with solid tumors newly initiating cancer treatment: results from the Cancer-VTE Registry. Thromb Res. 2022;213:203\u201313.","journal-title":"Thromb Res"},{"key":"1378_CR13","doi-asserted-by":"crossref","unstructured":"Brierley JD, Gospodarowicz MK, Wittekind C. TNM Classification of Malignant Tumours, 8th ed (Japanese ver.). Tokyo: Kanehara & Co., Ltd; 2017. [In Japanese].","DOI":"10.1002\/9780471420194.tnmc26.pub3"},{"issue":"35","key":"1378_CR14","first-page":"33","volume":"2008","author":"S Tanaka","year":"2001","unstructured":"Tanaka S, Nishigami K, Taniguchi N, Matsuo H, Hirai T, Kaneda S, et al. Criteria for ultrasound diagnosis of deep venous thrombosis of lower extremities. J Med Ultrason. 2001;2008(35):33\u20136 (Erratum in: J Med Ultrason (2001). 2010;37:223).","journal-title":"J Med Ultrason"},{"key":"1378_CR15","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1007\/s12185-008-0047-x","volume":"87","author":"H Nomura","year":"2008","unstructured":"Nomura H, Wada H, Mizuno T, Katayama N, Abe Y, Noda M, et al. Negative predictive value of D-dimer for diagnosis of venous thromboembolism. Int J Hematol. 2008;87:250\u20135.","journal-title":"Int J Hematol"},{"key":"1378_CR16","unstructured":"National Cancer Center Japan. Japan Cancer Statistics 2015. http:\/\/ganjoho.jp\/reg_stat\/statistics\/stat\/short_pred_past\/short_pred2015.html. Accessed 22 Aug 2022."},{"key":"1378_CR17","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1007\/s10120-016-0677-2","volume":"20","author":"Y Tanizawa","year":"2017","unstructured":"Tanizawa Y, Bando E, Kawamura T, Tokunaga M, Makuuchi R, Iida K, et al. Prevalence of deep venous thrombosis detected by ultrasonography before surgery in patients with gastric cancer: a retrospective study of 1140 consecutive patients. Gastric Cancer. 2017;20:878\u201386.","journal-title":"Gastric Cancer"},{"key":"1378_CR18","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s00423-021-02315-5","volume":"407","author":"K Suzuki","year":"2022","unstructured":"Suzuki K, Shibasaki S, Nakauchi M, Nakamura K, Akimoto S, Tanaka T, et al. Impact of routine preoperative sonographic screening with early intervention for deep venous thrombosis in lower extremities on preventing postoperative venous thromboembolism in patients with gastric cancer scheduled for minimally invasive surgery. Langenbecks Arch Surg. 2022;407:597\u2013608.","journal-title":"Langenbecks Arch Surg"},{"key":"1378_CR19","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1200\/JCO.19.01461","volume":"38","author":"SK Nigel","year":"2020","unstructured":"Nigel SK, Alok AK, Nicole MK, Kari B, Agnes YYL, Juan IA. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol. 2020;38:496\u2013520.","journal-title":"J Clin Oncol"},{"key":"1378_CR20","volume-title":"Japanese gastric cancer treatment guidelines 2021","author":"Japanese Gastric Cancer Association","year":"2021","unstructured":"Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2021. 6th ed. Tokyo: Kanehara & Co., Ltd.; 2021. [In Japanese].","edition":"6"},{"key":"1378_CR21","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.ejca.2011.11.016","volume":"48","author":"MJ Kang","year":"2012","unstructured":"Kang MJ, Ryoo BY, Ryu MH, Koo DH, Chang HM, Lee JL, et al. Venous thromboembolism (VTE) in patients with advanced gastric cancer: an Asian experience. Eur J Cancer. 2012;48:492\u2013500.","journal-title":"Eur J Cancer"},{"key":"1378_CR22","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1007\/s10120-019-00930-2","volume":"22","author":"K Takayoshi","year":"2019","unstructured":"Takayoshi K, Kusaba H, Aikawa T, Koreishi S, Sagara K, Nakano M, et al. Hypoalbuminemia for the prediction of venous thromboembolism and treatment of direct oral anticoagulants in metastatic gastric cancer patients. Gastric Cancer. 2019;22:988\u201398.","journal-title":"Gastric Cancer"},{"key":"1378_CR23","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.jamcollsurg.2020.08.734","volume":"231","author":"T Obitsu","year":"2020","unstructured":"Obitsu T, Tanaka N, Oyama A, Ueno T, Saito M, Yamaguchi T, et al. Efficacy and safety of low-molecular-weight heparin on prevention of venous thromboembolism after laparoscopic operation for gastrointestinal malignancy in Japanese patients: a multicenter, open-label, prospective, randomized controlled trial. J Am Coll Surg. 2020;231:501-9.e502.","journal-title":"J Am Coll Surg"},{"key":"1378_CR24","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1634\/theoncologist.2013-0226","volume":"18","author":"GH Lyman","year":"2013","unstructured":"Lyman GH, Eckert L, Wang Y, Wang H, Cohen A. Venous thromboembolism risk in patients with cancer receiving chemotherapy: a real-world analysis. Oncologist. 2013;18:1321\u20139.","journal-title":"Oncologist"},{"key":"1378_CR25","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1002\/ags3.12275","volume":"3","author":"T Hata","year":"2019","unstructured":"Hata T, Ikeda M, Miyata H, Nomura M, Gotoh M, Sakon M, et al. Frequency and risk factors for venous thromboembolism after gastroenterological surgery based on the Japanese national clinical database (516 217 cases). Ann Gastroenterol Surg. 2019;3:534\u201343.","journal-title":"Ann Gastroenterol Surg"},{"key":"1378_CR26","first-page":"215","volume":"110","author":"E Kovacova","year":"2009","unstructured":"Kovacova E, Kinova S, Duris I, Remkova A. General changes in hemostasis in gastric cancer. Bratisl Lek Listy. 2009;110:215\u201321.","journal-title":"Bratisl Lek Listy"},{"key":"1378_CR27","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1186\/s12885-017-3326-1","volume":"17","author":"H Kitayama","year":"2017","unstructured":"Kitayama H, Kondo T, Sugiyama J, Kurimoto K, Nishino Y, Hirayama M, et al. Venous thromboembolism in hospitalized patients receiving chemotherapy for malignancies at Japanese community hospital: prospective observational study. BMC Cancer. 2017;17:351.","journal-title":"BMC Cancer"}],"container-title":["Gastric Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-023-01378-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10120-023-01378-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-023-01378-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T15:38:28Z","timestamp":1687361908000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10120-023-01378-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,1]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["1378"],"URL":"https:\/\/doi.org\/10.1007\/s10120-023-01378-1","relation":{},"ISSN":["1436-3291","1436-3305"],"issn-type":[{"value":"1436-3291","type":"print"},{"value":"1436-3305","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,1]]},"assertion":[{"value":"30 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Takaki Yoshikawa received consultant fees from Daiichi Sankyo Co., Ltd. related to the submitted work, and received lecture fees from Covidien Japan, Inc., Otsuka Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., MSD K.K., Terumo Corp., EA pharma Co., Ltd., and Eli Lilly Japan K.K. outside the submitted work. Takeshi Sano received lecture fees from Taiho Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., and Ono Pharmaceutical Co., Ltd., outside the submitted work. Masanori Terashima received consultant fees from Daiichi Sankyo Co., Ltd. related to the submitted work, and received lecture fees from Taiho Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Bristol-Myers Squibb K.K., Yakult Honsha Co., Ltd., Takeda Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., Pfizer Japan Inc., Daiichi Sankyo Co., Ltd., Johnson & Johnson K.K., Medtronic Japan Co., Ltd., Intuitive Surgical Japan Inc., and Olympus Corp, outside the submitted work. Kensei Yamaguchi received consulting fees from Daiichi Sankyo Co., Ltd. related to the submitted work, and received lecture fees from Daiichi Sankyo Co., Ltd., Chugai Pharmaceutical Co., Ltd., Bristol-Myers Squibb K.K., Eli Lilly Japan K.K., Taiho Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., and Merck Biopharm Co., Ltd., outside\u00a0the submitted work. Etsuro Bando received lecture fees from Johnson & Johnson K.K., Covidien Japan Inc., Intuitive Surgical Inc., and Kaken Pharmaceutical Co., Ltd., outside the\u00a0submitted work. Hisashi Shinohara received lecture fees from Johnson & Johnson K.K., Medtronic Japan Co., Ltd., Olympus Corp., Taiho Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Bristol-Myers Squibb K.K., MSD K.K., Terumo Corp., and Eli Lilly Japan K.K outside the submitted work. Mari S Oba received lecture fees from SAS Institute Inc., EP SOGO Co., Ltd., Pfizer Japan Inc., and AstraZeneca K.K. related to the submitted work. Tetsuya Kimura and Atsushi Takita are employees of Daiichi Sankyo Co., Ltd. Mitsuru Sasako received lecture and consulting fees from Daiichi Sankyo Co., Ltd. related to the submitted work, and received lecture and consulting fees from Ono Pharmaceutical Co., Ltd., and lecture fees from Ono Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., Nippon Kayaku Co., Ltd., Taiho Pharmaceutical Co., Ltd., and Chugai Pharmaceutical Co., Ltd. outside the submitted work. Ryohei Kawabata and Hiroshi Yabusaki have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions. Informed consent to be included in the study was obtained from all patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}